Viewing Study NCT01208961

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:58 PM
Ignite Modification Date: 2026-01-27 @ 1:46 AM
Study NCT ID: NCT01208961
Status: COMPLETED
Last Update Posted: 2015-07-15
First Post: 2010-09-23
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Severe Hypertriglyceridemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Eicosapentaenoic Acid View
None Docosahexaenoic Acid View
None Hypertriglyceridemia View
None Omega-3 acid ethyl esters View
None Omega-3 carboxylic acids View
None Epanova View
None Lovaza View
None bioavailability View
None pharmacokinetics View
None low-fat meal View
None high-fat meal View